Otsuka Pharmaceutical Development & Commercialization, Inc.
Clinical trials sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., explained in plain language.
-
New schizophrenia drug safety checked in teens for two years
Disease control CompletedThis study aimed to understand the long-term safety and side effects of the medication brexpiprazole in teenagers (ages 13-17) with schizophrenia. Nearly 300 adolescents took a flexible dose of the drug for up to two years while researchers closely monitored their health. The mai…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New pill aims to curb binge eating episodes
Disease control CompletedThis study tested whether a new, once-daily pill called centanafadine could help reduce binge eating days in adults with moderate to severe binge eating disorder. Researchers compared two different doses of the medication against a placebo (a pill with no medicine) in 147 partici…
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for tough depression: Add-On drug shows promise
Disease control CompletedThis study tested whether adding an experimental drug called SEP-363856 to standard antidepressants helps adults whose depression hasn't improved enough with previous treatments. About 929 adults with major depressive disorder participated in this late-stage trial. Researchers co…
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New schizophrenia drug tested in medication switch study
Disease control CompletedThis study tested how well people with schizophrenia could switch from their current antipsychotic medication to a new drug called SEP-363856. 101 participants took the new drug for 8 weeks while researchers monitored how many stopped treatment due to side effects or lack of bene…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New schizophrenia drug faces final safety check
Disease control CompletedThis study tested the long-term safety of an experimental schizophrenia medication called SEP-363856. It involved 75 people with schizophrenia who had already switched to this drug from their previous antipsychotic medication in an earlier trial. Researchers monitored participant…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Scientists test new ADHD pill formulas in healthy volunteers
Disease control CompletedThis early-stage study tested different capsule versions of an experimental drug called centanafadine, which is being developed for ADHD. Researchers gave the pills to 174 healthy adults to see if different capsule strengths worked the same, if food affected absorption, and how t…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
First humans test new psoriasis antibody
Disease control CompletedThis first-in-human study tested the safety and how the body processes CAN10, a new antibody being developed for plaque psoriasis. The trial involved 80 healthy volunteers and people with mild to moderate psoriasis, testing single and repeated doses. Researchers monitored side ef…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Year-Long test for new schizophrenia pill compares safety to existing treatment
Disease control CompletedThis study aimed to see if a new, experimental schizophrenia medication called SEP-363856 is safe for people to take for a full year. It compared the drug's long-term safety and side effects to an already-approved medication, quetiapine XR. The trial involved 305 clinically stabl…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC
-
New drug trial targets uncontrollable anger after head trauma
Symptom relief CompletedThis study tested whether an investigational drug called AVP-786 could help reduce severe behavioral problems like aggression, agitation, and irritability in people who have had a traumatic brain injury (TBI). 168 participants were randomly assigned to receive either the drug or …
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Apr 01, 2026 14:41 UTC
-
New anxiety pill tested in global trial shows promise
Symptom relief CompletedThis clinical trial tested whether an investigational medication called SEP-363856 could safely reduce anxiety symptoms in adults with generalized anxiety disorder. About 434 participants across roughly 65 global sites took either the medication or a placebo pill daily for 8 week…
Phase: PHASE2, PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Mar 25, 2026 14:08 UTC
-
Drug maker tests if two small pills equal one big one
Knowledge-focused CompletedThis study aimed to see if taking two lower-strength pills of the drug centanafadine is equivalent to taking one higher-strength pill. It involved 44 healthy adult volunteers who took the drug in different forms. The main goal was to compare how the body absorbs and processes the…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Drug absorption test: pill vs. capsule
Knowledge-focused CompletedThis study aimed to see how a new pill version of the drug centanafadine compares to an existing capsule version in how the body absorbs it. It involved 62 healthy adult volunteers who took one of the two forms. The main goal was to measure the levels of the drug in the blood ove…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:41 UTC
-
Scientists test how new mental health drug mixes with others
Knowledge-focused CompletedThis early study tested how a potential schizophrenia medication (SEP-380135) might interact with other drugs in the body. Researchers gave the drug to 12 healthy adults to measure how their bodies processed it and check for safety issues. The goal was to understand potential dru…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:40 UTC
-
Scientists trace a single Pill's journey through the body
Knowledge-focused CompletedThis early-stage study aimed to understand how a new drug called OPC-167832 is processed by the body. Eight healthy male volunteers took a single oral dose containing a tiny, safe amount of radioactive tracer. Researchers then measured how much of the drug was absorbed, how long …
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:08 UTC